Evidence map›Paper›PMID 35887554›Full record

ArticleJournal of personalized medicine2022

Clinical Predictors for Procedural Stroke and Implications for Embolic Protection Devices during TAVR: Results from the Multicenter Transcatheter Aortic Valve Replacement In-Hospital Stroke (TASK) Study.

Anat Berkovitch, Amit Segev, Elad Maor, Alexander Sedaghat, Ariel Finkelstein, Matteo Saccocci, Ran Kornowski, Azeem Latib, Jose M De La Torre Hernandez, Lars Søndergaard and 16 more

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 11 institutions in 11 countries.

Anat BerkovitchInterventional Cardiology Unit, Leviev Heart and Vascular Center, Chaim Sheba Medical Center, Ramat Gan 5262000, Israel.ORCID 0000-0002-4589-5296
Amit SegevInterventional Cardiology Unit, Leviev Heart and Vascular Center, Chaim Sheba Medical Center, Ramat Gan 5262000, Israel.
Elad MaorInterventional Cardiology Unit, Leviev Heart and Vascular Center, Chaim Sheba Medical Center, Ramat Gan 5262000, Israel.
Alexander SedaghatHeart Center Bonn, University Hospital Bonn, 53127 Bonn, Germany.
Ariel FinkelsteinSackler School of Medicine, Tel-Aviv University, Tel Aviv 69978, Israel.
Matteo SaccocciCardiovascular Surgery Department, University Hospital of Zurich, CH-8091 Zurich, Switzerland.ORCID 0000-0002-0843-9240
Ran KornowskiSackler School of Medicine, Tel-Aviv University, Tel Aviv 69978, Israel.ORCID 0000-0002-7708-8253
Azeem LatibDepartment of Cardiology, Montefiore Medical Center, New York, NY 10467, USA.ORCID 0000-0001-9035-343X
Jose M De La Torre HernandezInterventional Cardiology Department, Hospital Universitario Marques de Valdecilla, 39008 Santander, Spain.
Lars SøndergaardThe Heart Center, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.
Darren MylotteUniversity Hospital and SAOLTA Health Care Group, National University of Ireland, H91 TK33 Galway, Ireland.
Niels Van RoyenDepartment of Cardiology, Radboud University Medical Center, Postbus 9101, 6500 HB Nijmegen, The Netherlands.
Azfar G ZamanCardiology, Freeman Hospital and Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne NE1 7RU, UK.
Pierre RobertDepartment of Interventional Cardiology, Clinique Pasteur, 31300 Toulouse, France.
Jan-Malte SinningHeart Center Bonn, University Hospital Bonn, 53127 Bonn, Germany.
Arie SteinvilSackler School of Medicine, Tel-Aviv University, Tel Aviv 69978, Israel.
Francesco MaisanoCardiovascular Surgery Department, University Hospital of Zurich, CH-8091 Zurich, Switzerland.
Katia OrvinSackler School of Medicine, Tel-Aviv University, Tel Aviv 69978, Israel.
Gianmarco IannopolloInterventional Cardiology Unit, San Raffaele Hospital, 10090 Milan, Italy.
Dae-Hyun LeeThe Heart Center, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.
Ole De BackerUniversity Hospital and SAOLTA Health Care Group, National University of Ireland, H91 TK33 Galway, Ireland.
Federico MercantiDivision of Cardiology, University of Rome Tor Vergata, 00173 Rome, Italy.
Kees van der WulpCardiology, Freeman Hospital and Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne NE1 7RU, UK.ORCID 0000-0001-5363-6510
Joy ShomeDepartment of Interventional Cardiology, Clinique Pasteur, 31300 Toulouse, France.
Didier TchétchéInterventional Cardiology Unit, San Raffaele Hospital, 10090 Milan, Italy.
Israel M BarbashInterventional Cardiology Unit, Leviev Heart and Vascular Center, Chaim Sheba Medical Center, Ramat Gan 5262000, Israel.
Tel Aviv University · ILClinique Pasteur · FRFreeman Hospital · GBNational University of Ireland · IERigshospitalet · DKUniversity Hospital Bonn · DEUniversity Hospital of Zurich · CHMarqués de Valdecilla University Hospital · ESMontefiore Medical Center · USRadboud University Nijmegen · NLUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Data to support the routine use of embolic protection devices for stroke prevention during transcatheter aortic valve replacement (TAVR) are controversial. Identifying patients at high risk for peri-procedural cerebrovascular events may facilitate effective patient selection for embolic protection devices during TAVR. Aim: To generate a risk score model for stratifying TAVR patients according to peri-procedural cerebrovascular events risk. Methods and results: A total of 8779 TAVR patients from 12 centers worldwide were included. Peri-procedural cerebrovascular events were defined as an ischemic stroke or a transient ischemic attack occurring ≤24 h from TAVR. The peri-procedural cerebrovascular events rate was 1.4% (n = 127), which was independently associated with 1-year mortality (hazards ratio (HR) 1.78, 95% confidence interval (CI) 1.06−2.98, p < 0.028). The TASK risk score parameters were history of stroke, use of a non-balloon expandable valve, chronic kidney disease, and peripheral vascular disease, and each parameter was assigned one point. Each one-point increment was associated with a significant increase in peri-procedural cerebrovascular events risk (OR 1.96, 95% CI 1.56−2.45, p < 0.001). The TASK score was dichotomized into very-low, low, intermediate, and high (0, 1, 2, 3−4 points, respectively). The high-risk TASK score group (OR 5.4, 95% CI 2.06−14.16, p = 0.001) was associated with a significantly higher risk of peri-procedural cerebrovascular events compared with the low TASK score group. Conclusions: The proposed novel TASK risk score may assist in the pre-procedural risk stratification of TAVR patients for peri-procedural cerebrovascular events.

Indexed as

aortic stenosisstroketranscatheter aortic valve replacement

Identifiers

PMID35887554
PMCPMC9316224
OpenAlexW4283696943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.